Construction of a New Mishima Plant and Transition to a Dual-Site Production System
First written in FY2024. 2 of 7 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026.
9 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「We will improve productivity and quality by strengthening the antigen testing production system centered on the Mt. Fuji Mishima Plant, automating manufacturing and testing lines, and optimizing production planning using data, AI and other technologies.」
Following the start of operations at the new plant, the company has been advancing automation and data- and AI-based production planning optimization on the assumption of production at two sites. - FY2026-H1AchievedAnnual report
「The Fujisan Mishima Plant will commence full-scale operations as scheduled from 2 February 2026.」
The new plant, which had been scheduled to begin operations in February 2026, reached the stage of commencing full-scale operations as scheduled on 2 February. - FY2025SoftenedAnnual report
「As a fundamental measure, we are constructing a new plant in Mishima City and aim to begin operations in February 2026.」
The target start date was pushed back from December 2025 to February 2026. Investment in the buildings and production equipment of the New Mishima Plant continued, with plans to increase monthly production capacity from 1.3 million tests to 3.9 million tests and disclosure of plant-related assets exceeding ¥9.7 billion. - FY2025-H1AdvancedAnnual report
「This was mainly due to an increase in trade receivables accompanying the substantial growth in revenue resulting from the influenza outbreak in December, as well as an increase in construction in progress related to the construction of the new plant. Cash decreased by ¥4,664.086 million through investing activities, mainly due to payments for the acquisition of property, plant and equipment associated with construction of the new plant.」
Construction in progress related to the new plant increased to ¥7,610.332 million, and ¥4,118.389 million was spent on property, plant and equipment, indicating that the construction plan had progressed to the stage of concrete investment and asset recognition. The disclosure did not state that operations had begun or that the two-site production system had been completed. - FY2024First statedAnnual report
「As a fundamental measure, we are constructing a new plant in Mishima City and aim to begin operations in December 2025.」
The new plant is intended to expand existing lines, accommodate new products, introduce factory automation, provide inventory storage, and establish a two-site production system for BCP. Monthly production capacity is expected to increase from 1.3 million tests to 3.9 million tests.